5-bromo-N-[2-(4-methylpiperazin-1-yl)ethyl]-4-(1-methylpyrrole-2-carboximidoyl)-6-phenylpyridazin-3-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-bromo-N-[2-(4-methylpiperazin-1-yl)ethyl]-4-(1-methylpyrrole-2-carboximidoyl)-6-phenylpyridazin-3-amine
• 化学式: C₂₃H₂₈BrN₇
• 分子量: 482.4
• InChiKey: UHRYSWPJVFYHET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  73.1
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME<br/>[FR] PYRAZOLOPYRIDAZINES ET MÉTHODES DE TRAITEMENT DE MALADIES DÉGÉNÉRATIVES DE LA RÉTINE ET DE LA PERTE D'AUDITION ASSOCIÉE AU SYNDROME D'USHER
  申请人：USHER III INITIATIVE INC

  公开号：WO2014066836A1

  公开（公告）日：2014-05-01

  Compounds, compositions and methods for the treatment of retinal degenerative diseases, such as retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related macular degeneration and Usher Syndrome, and hearing loss associated with Usher Syndrome are described herein. Usher Syndrome, a rare genetic disorder and a leading cause of deafness and blindness, is associated with a mutation in any one of ten genes.